From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Monoclonal antibody
TypeWhole antibody
Targetbeta amyloid
Clinical data
ATC code
  • none
CAS Number
  • none
Chemical and physical data
Molar mass145.9 kg/mol g·mol−1

Aducanumab is a human monoclonal antibody that is being studied for the treatment of Alzheimer's disease (AD).[1] It is being developed by Biogen Inc., which licensed the drug candidate from Neurimmune, its discoverer.[2] The antibody targets aggregated forms of β-amyloid (Aβ) in the hopes of reducing its buildup.[3]


Interim results from the second Phase 1 study of the drug were reported in March 2015.[1][4]

A phase Ib study was published in August 2016, based on one year of "monthly intravenous infusions" of aducanumab, with brain scans to measure amyloid plaques.[5] Phase 3 clinical trials are ongoing.[5]


  1. ^ a b Cynthia Fox for Drug Discovery and Development (April 28, 2015). "The Story of Biogen's Alzheimer's Drug, Aducanumab".
  2. ^ Rebecca Zacks for Xconomy (November 20, 2007). "Biogen Inks $380 Million Deal with Swiss Company".
  3. ^ Toyn, Jeremy (2015). "What lessons can be learned from failed Alzheimer's disease trials?". Expert Rev. Clin. Pharmacol. 8 (3): 267–269. doi:10.1586/17512433.2015.1034690. PMID 25860157.
  4. ^ Matthew Herper for Forbes. March 20, 2015 Biogen Drug Could Inspire New Hope For Alzheimer's Treatments
  5. ^ a b Sevigny J.; Chiao P.; Bussière T.; Weinreb P.H.; Williams L.; Maier M.; Dunstan R.; Salloway S.; Chen T.; Ling Y.; O'Gorman J.; Qian F.; Arastu M.; Li M.; Chollate S.; Brennan M.S.; Quintero-Monzon O.; Scannevin R.H.; Arnold H.M.; Engber T.; Rhodes K.; Ferrero J.; Hang Y.; Mikulskis A.; Grimm J.; Hock C.; Nitsch R.M.; Sandrock A. (1 September 2016). "The antibody aducanumab reduces Aβ plaques in Alzheimer's disease". Nature. 537 (7618): 50–56. doi:10.1038/nature19323. PMID 27582220.